Link to our ongoing European clinical Ph IIb trial in Parkinson´s disease dyskinesia (NCT03956979)
Bukwang Pharmaceutical Co Ltd
BDD Pharma
University of Copenhagen
Recent News
September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more
Contact us
Contera Pharma Headquarter
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
